HBsAg Rapid Test Strip

INTENDED USE

HBsAg Rapid Test is a lateral flow immunochromatographic assay for the qualitative determination of Hepatitis B surface antigen (HBsAg) in human serum or plasma. It is intended for the screening of blood and blood products to be used for transfusion and an aid for the diagnosis of existing or previous hepatitis B infection. The test is recommended for professional use only. All results must be interpreted together with other clinical information or other diagnosis methods available to the physician.

PERFORMANCE

Sensitivity

HBsAg Rapid Test has been tested with a sensitivity panel ranging from 0 to 300ng/mL. All 10 HBsAg subtypes produced positive results on HBsAg Rapid Test. The test can detect 5 ng/ml of HBsAg in 10 minutes, and 1 ng/ml of HBsAg in 20 minutes.

Specificity:

Antibodies used for HBsAg Rapid Test were developed against whole Hepatitis B antigen isolated from Hepatitis B virus. Specificity of HBsAg Rapid Test was also tested with laboratory strains of Hepatitis A and Hepatitis C. They all yielded negative results.

HBsAg Rapid Test Strip vs. EIA test

The test results for HBsAg Rapid Test are as below:

Relative Sensitivity: 99.4%

Relative Specificity: 99.5%

Accuracy: 99.5%

Accuracy

Intra-assay:

Within-run precision was determined using 10 replicates of three specimens containing 0, 1 and 5 ng/ml of HBsAg. The negative and positive values were correctly identified in 100% of cases.

Inter-assay:

Between-run precision was determined using the same three specimens of 0, 1 and 5 ng/ml of HBsAg in 10 independent assays and with three different batches of HBsAg rapid test over a 6 month period. Again, the negative and positive values were correct in 100% of cases.

Shenzhen Kisshealh Biotechnology Co., Ltd., located in the Pingshan District, Shenzhen, P.R. China. is a diagnostics company focused on the development and manufacture of IVD tests at the Point-of-Care with highly innovative proprietary technology.

We focused on the emerging markets of in vitro pathological diagnosis and immunodiagnosis. We developed, manufactured and successfully launched the in vitro immunodiagnosis platform for cancer and the POCT for infectious, genetic and chronic diseases.

<span style="color: rgb(33, 33, 33); text-transform: none; text-indent: 0px; letter-spacing: normal;" initial;"="" initial;="" 0px;="" normal;="" 255);="" 255,="" rgb(255,="" 2;="" !important;="" inline="" none;="" 600;="" 14px;="" sans-serif;="" arial,="" roboto,="" w3",="" gb="" sans="" "hiragino="" gb",="" hei",="" micro="" "wenquanyi="" sans",="" "droid="" arimo,="" freesans,="" yahei",="" "microsoft="" helvetica,="" grande",="" "lucida="" ui",="" segoe="">At Kissh we work every day to shape the future of in-vitro diagnostic testing. And our people are our best asset, the reason for our track record and our strength while we are moving forward. We live by our fundamental values and incorporate them in everything that we do. Our best asset is ‘Step Forward Every Second’